Fennec Pharmaceuticals Inc (NASDAQ: FENC) has reported E.P.S. of $-0.10 for its fourth fiscal quarter (ending December 31) versus $-0.26 for the same period a year ago. For the latest four quarters through December 31, E.P.S. were $-0.60 compared to $-0.90 a year ago.
Recent Price Action
On 3/21/24, Fennec Pharmaceuticals Inc (NASDAQ: FENC) stock was unchanged 0.0%, closing at $11.07. However, this flat performance was accompanied by exceptionally low trading volume at 0% of normal. Relative to the market the stock has been exceptionally strong over the last nine months and has risen 11.8% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, FENC is expected to be a major Value Eraser.
Fennec Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment